CoreTissue BioEngineering
PrivateLast Round
Grant
Jan 9, 2026
Total Funding Raised
$11.36M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
CoreTissue BioEngineering operates in Healthcare & Life Sciences and is based in Yokohama. Its latest recorded funding round was a Grant round in January 2026.
CoreTissue BioEngineering is a bioengineering company that develops, manufactures, and sells medical devices using proprietary decellularization technology for anterior cruciate ligament reconstruction.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Biotechnology, Clinical Trials
Business Model
B2B
Customer Profile
Hardware Sales
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
CoreTissue BioEngineering Comparables
Compare CoreTissue BioEngineering with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Miach Orthopaedics | 79% | |
| Arthrex | 65% | |
| Johnson & Johnson | 64% |
For institutional investors. Book with your work email.
CoreTissue BioEngineering Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Jan 9, 2026 | ||||
| Series A Extension | Nov 10, 2025 | ||||
| Accelerator | Jul 29, 2024 | ||||
| Series A | Jan 1, 2023 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
CoreTissue BioEngineering Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| New Energy and Industrial Technology Development Organization | Grant |
| WERU Investment Co. | Series A Extension |
| Japan Science and Technology Agency | Series A |
| Mitsui Sumitomo Insurance Capital Co., Ltd. | Series A Extension |
| Fogarty Innovation | Accelerator |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 14, 2026
Monthly visitors increased 65% MoM, reaching 1.5K.
- Jan 1, 2023
$4.3M round with participation from AXA and JST.
For institutional investors. Book with your work email.
CoreTissue BioEngineering Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about CoreTissue BioEngineering's valuation, stock price, and market status.
Is CoreTissue BioEngineering a public or private company?
CoreTissue BioEngineering is a private company.
What is the current stock price of CoreTissue BioEngineering?
CoreTissue BioEngineering is a private company, so its shares have no public market price. Caplight tracks CoreTissue BioEngineering's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is CoreTissue BioEngineering worth (valuation)?
Valuation information for CoreTissue BioEngineering is not publicly available.
Can I buy CoreTissue BioEngineering stock?
CoreTissue BioEngineering shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was CoreTissue BioEngineering's last funding round?
CoreTissue BioEngineering's most recent funding round was Grant on January 9, 2026.
Who are the main investors in CoreTissue BioEngineering?
Key investors in CoreTissue BioEngineering include New Energy and Industrial Technology Development Organization, WERU Investment Co., Japan Science and Technology Agency, Mitsui Sumitomo Insurance Capital Co., Ltd., Fogarty Innovation.
Will CoreTissue BioEngineering IPO soon?
No public IPO plans have been announced for CoreTissue BioEngineering.
How can I track CoreTissue BioEngineering secondary market activity?
Caplight tracks bids, offers, and trades in CoreTissue BioEngineering's shares on secondary markets.